c277dab0-361f-4aa6-96b1-522a6e556ae1
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 77
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.630
- INFLAMMATORY_RESPONSE+0.470
- ALLOGRAFT_REJECTION+0.460
- ANGIOGENESIS+0.460
- INTERFERON_ALPHA_RESPONSE+0.460
- INTERFERON_GAMMA_RESPONSE+0.450
- IL6_JAK_STAT3_SIGNALING+0.440
- KRAS_SIGNALING_UP+0.380
- UV_RESPONSE_DN+0.380
- COMPLEMENT+0.370
Top 10 suppressed
- MYC_TARGETS_V2-0.530
- OXIDATIVE_PHOSPHORYLATION-0.510
- E2F_TARGETS-0.440
- MYC_TARGETS_V1-0.440
- G2M_CHECKPOINT-0.380
- GLYCOLYSIS-0.360
- FATTY_ACID_METABOLISM-0.320
- PEROXISOME-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.300
- DNA_REPAIR-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 2cec663c-00c8-48b5-967b-f2a53c0fb409 | — | — | 0.961 |
| 2 | 80cb0e05-387d-4bd8-b49c-ff2aae043982 | — | — | 0.954 |
| 3 | TCGA-AN-A0FN-01A-11R-A034-07 | — | A | 0.951 |
| 4 | f22cfa82-a346-4fed-bc81-21a29bf990ee | — | — | 0.947 |
| 5 | ec054d40-e5b8-496a-8c99-5e7f88f2cf37 | — | — | 0.945 |
| 6 | TCGA-55-7227-01A-11R-2039-07 | — | cohortA1 | 0.945 |
| 7 | TCGA-D8-A141-01A-11R-A115-07 | — | A | 0.945 |
| 8 | C3N-02923 | — | cohortMD2 | 0.944 |
| 9 | TCGA-CR-7376-01A-11R-2132-07 | — | — | 0.944 |
| 10 | SRR12202441 | — | — | 0.943 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.630 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.470 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.460 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.460 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.460 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.450 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.440 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.380 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.380 | Inavolisib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.320 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.320 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.320 | Inavolisib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.290 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.250 | Inavolisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |